AnteCRC is a genetic test that assesses a person’s risk of developing colorectal cancer using the polygenic risk score (PRS) methodology.
Colorectal cancer is a malignant cancer with a high mortality rate and usually develops for many years without symptoms. Therefore, prevention and early detection of colorectal cancer are crucial. AnteCRC uses dozens of colorectal cancer genetic variants to calculate the risk. The purpose of the test is to reduce the risk of premature mortality due to colorectal cancer through primary prevention and screening.
AnteCRC is a registered in vitro diagnostic device (IVD medical device) and it has been developed by the healthcare service provider Antegenes (License: L04685).
What does AnteCRC test include?
- Analyzes of 91 genetic variants associated with colorectal cancer;
- Individual polygenic risk score for colorectal cancer;
- The individual risk of colorectal cancer compared to the rest of the population;
- Likelihood to get colorectal cancer in 10 years and risk assessment compared to a person with average genetic risk;
- Interpretation of the test results with clinical recommendations;
- Genetic counseling.
Who can benefit from AnteCRC?
AnteCRC test is recommended for:
- Men and women between the ages of 40-75 of European origin (Note: Genetic risk studies used by AnteCRC have been conducted in populations of European descent).
The AnteCRC test is not recommended:
- If the patient has a high-risk mutation in a single gene predisposed to colorectal cancer (e.g. APC, KRAS, TP53, MLH1, MSH2, MSH6, PMS2, STK11, MUTYH).
What is needed for AnteCRC testing?
AnteCRC testing requires the patient’s DNA, which is collected and isolated from the buccal swab sample (cells inside the cheek are collected with a special cotton swab).
How long does it take to get AnteCRC test results?
Test results are available within 6 weeks from the sample being received by Antegenes.
AnteCRC Test Limitations
- AnteCRC test is not used to diagnose colorectal cancer.
- AnteCRC test is not validated for use by individuals of non-European descent.
- An elevated risk estimated by the AnteCRC test does not mean that the patient will develop colorectal cancer during their lifetime. Also, a moderate or lower risk does not mean that the patient will not develop the disease.
- AnteCRC test is patient-specific and does not assess the risk of the patient’s family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children.
- AnteCRC test does not analyze rare pathogenic mutations in genes that significantly increase the risk of colorectal cancer, such as APC, KRAS, TP53, MLH1, MSH2, MSH6, PMS2, STK11, MUTYH and others.
- The AnteCRC test is based on the most up-to-date scientific data, which may, however, be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results.
- Different polygenic risk scores predicting risks of the same trait may give different estimates of the individual’s risks due to differences in the genetic variants included in the models and their weights.
- The results of this test should be applied in context with other relevant clinical data. In addition to the possible genetic predisposition, other risk factors also influence the risk of colorectal cancer.